Clinical Observation on the Treatment of Diabetic Kidney Disease with Damp-heat Stasis Syndrome in Clinical Proteinuria Stage by Kunkui Kidney Preserving Paste

[Objectives]To evaluate the clinical efficacy and safety of Kunkui Kidney Preserving Paste in the treatment of diabetic kidney disease(DKD)patients with damp-heat stasis syndrome in the clinical proteinuria stage.[Methods]Retrospective analysis was made on 30 patients with DKD who were diagnosed with damp-heat stasis syndrome in the clinical proteinuria stage from March 2021 to March 2023 in Jiangsu Province Hospital of Chinese Medicine,and who took Kunkui Kidney Preserving Paste continuously for six months.The urinary albumin/creatinine ratio(UACR),urinary complement C3,and urea nitrogen(BUN)of DKD patients before and after treatment were compared,and estimated glomerular filtration rate(eGFR),blood creatinine(Scr),and cystatin C(CysC)were estimated,and the therapeutic effects on renal function and urinary protein were evaluated.[Results]After treatment,UACR significantly decreased(P<0.01),and urinary complement C3 and Scr decreased(P<0.05),while other indicators showed no significant statistical difference(P>0.05).In terms of evaluating the efficacy of urinary protein therapy,8 cases showed recent relief;8 cases showed significant effect;9 cases were effective,and 5 cases were invalid after treatment,with a total effective rate of 83.33%.In terms of renal function efficacy evaluation,8 cases showed significant effect;4 cases were effective;11 cases were stable,and 7 cases were invalid,with a total effective rate of 76.67%.In the safety evaluation,there were no obvious adverse reactions.[Conclusions]The Kunkui Kidney Preserving Past has significant clinical efficacy and safety in treating DKD patients with damp-heat stasis syndrome in the clinical proteinuria period.It has significant advantages in reducing urinary protein and protecting renal function,which is worthy of clinical promotion.

火把花根片联合黄葵胶囊治疗高或极高进展风险糖尿病肾病的临床探索

目的探讨火把花根片联合黄葵胶囊治疗高或极高进展风险糖尿病肾病患者的临床疗效及安全性。方法将江苏省中医院2021年3月至2023年3月门诊或病房收治的高或极高进展风险的糖尿病肾病患者作为研究对象,采用随机数字表法分为对照组和观察组,各55例。对照组给予黄葵胶囊治疗,观察组在对照组治疗的基础上联合火把花根片治疗,2组均治疗6个月。比较2组治疗前后的尿微量蛋白/肌酐比值(UACR)、估算的肾小球滤过率(eGFR)、血肌酐、胱抑素C、肾功能及尿蛋白的疗效评估及不良反应情况。结果观察组治疗后UACR和血肌酐下降,eGFR升高(P均<0.05),胱抑素C呈下降趋势,但无统计学意义(P>0.05);对照组治疗后UACR、血肌酐和eGFR均呈下降趋势,但差异无统计学意义(P均>0.05),胱抑素C上升(P<0.05)。观察组UACR、eGFR、胱抑素C治疗前后的改善幅度(ΔUACR、ΔeGFR和Δ胱抑素C)均明显优于对照组(P均<0.05)。在肾功能疗效评估方面,治疗后观察组显效14例,有效8例,稳定18例,无效12例,总有效率为76.92%;对照组显效6例,有效6例,稳定11例,无效28例,总有效率为45.1%;2组总有效率差异有统计学意义(P<0.05)。在尿蛋白疗效评估方面,治疗后观察组近期缓解14例,显效10例,有效16例,无效12例,总有效率为76.92%;对照组近期缓解8例,显效6例,有效19例,无效18例,总有效率为64.71%;观察组治疗蛋白尿的总有效率高于对照组,但差异无明显统计学意义(P>0.05)。在安全性评价中,观察组患者与对照组患者的不良反应率无明显统计学意义(7.69%vs 3.92%,P>0.05)。结论火把花根片联合黄葵胶囊对高或极高进展风险的糖尿病肾病患者临床疗效显著,安全性较好,在降低尿蛋白和保护肾功能方面具有显著优势,值得临床推广。